A phase II study of nedaplatin plus irinotecan for stage III/IV and EGFR mutation negative non-small cell lung cancer with high-risk factors.

Trial Profile

A phase II study of nedaplatin plus irinotecan for stage III/IV and EGFR mutation negative non-small cell lung cancer with high-risk factors.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs Irinotecan (Primary) ; Nedaplatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jan 2013 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 21 Nov 2012 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
    • 07 Oct 2011 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top